Home Alzheimer’s Disease Sumanta K. Pal, MD, FASCO, on Cabozantinib Efficacy in SWOG 1500 for...

Sumanta K. Pal, MD, FASCO, on Cabozantinib Efficacy in SWOG 1500 for Papillary RCC

Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.

CancerNetwork® spoke with Sumanta K. Pal, MD, FASCO, at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium (GU) regarding the SWOG 1500 trial (NCT02761057) investigating sunitinib (Sutent) versus cabozantinib (Cabometyx), crizotinib (Xalkori), or savolitinib to treat patients with metastatic papillary renal cell carcinoma.

Transcription:

This is a really big study. This is the first time that we have a systemic therapy regimen that’s shown benefit in papillary kidney cancer. This is quite groundbreaking; truly, this is one of those findings that you can hear at ASCO GU over the weekend and take back to the clinic on Monday morning and implement. You know, the study is the first…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments